New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
15:20 EDTFURX, ACTFuriex stockholders approve acquisition by Actavis
The stockholders of Furiex Pharmaceuticals (FURX) voted at a special meeting to adopt the previously announced agreement and plan of merger, dated as of April 27, providing for the merger of Furiex with an entity now controlled by Forest Laboratories, a subsidiary of Actavis (ACT). Furiex also announced that it has received notice of clearance of the proposed merger from the Ukrainian Antimonopoly Committee. Actavis completed its acquisition of Forest Laboratories on July 1.
News For FURX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 14, 2015
06:18 EDTACTActavis urges U.S. appeals court to reverse decision on Namenda, AP reports
Subscribe for More Information
April 13, 2015
16:37 EDTACTActavis announces availability of 52mg Liletta to prevent pregnancy
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that Liletta 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
10:52 EDTACTMeister says Actavis bought great companies, can continue growing
Subscribe for More Information
09:27 EDTACTActavis and Medicine360 announce Liletta es available in the U.S.
Subscribe for More Information
08:34 EDTACTZoetis names Actavis Executive Chairman Paul Bisaro to board
Subscribe for More Information
April 9, 2015
11:39 EDTACTPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
April 8, 2015
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use